Amgen (AMGN) EBT (2016 - 2026)

Amgen has reported EBT over the past 18 years, most recently at $2.1 billion for Q1 2026.

For Q1 2026, EBT rose 5.63% year-over-year to $2.1 billion; the TTM value through Mar 2026 reached $9.1 billion, up 36.65%, while the annual FY2025 figure was $9.0 billion, 94.75% up from the prior year.
EBT for Q1 2026 was $2.1 billion at Amgen, up from $1.5 billion in the prior quarter.
Over five years, EBT peaked at $3.9 billion in Q3 2025 and troughed at -$68.0 million in Q1 2024.
A 5-year average of $1.8 billion and a median of $1.7 billion in 2022 define the central range for EBT.
Biggest five-year swings in EBT: tumbled 101.98% in 2024 and later surged 3001.47% in 2025.
Year by year, EBT stood at $1.7 billion in 2022, then tumbled by 51.26% to $852.0 million in 2023, then decreased by 8.22% to $782.0 million in 2024, then surged by 93.61% to $1.5 billion in 2025, then surged by 37.65% to $2.1 billion in 2026.
Business Quant data shows EBT for AMGN at $2.1 billion in Q1 2026, $1.5 billion in Q4 2025, and $3.9 billion in Q3 2025.

Peer Comparison